DUBLIN, IRELAND, Privately-held, biopharmaceutical development raises EURO 3 million.
Sigmoid Pharma Completes Phase II trial of CyCol in more than 100 Ulcerative Colitis Patients and Raises EURO3 million.
Sigmoid Pharma is headquartered at the "Invent Centre" advanced technologies incubator on the campus of Dublin City University in Ireland's capital city.
The company has developed two proprietary oral pharmaceutical formulation technologies known as LEDDS (liquid/emulsion drug delivery system) and SmPill (single-multiple pill) which it employs in developing its own products as well as those of partners.
The company, formerly known as Sigmoid Biotechnologies, was founded in 2003 to exploit know-how in the areas of oral drug formulation and the science of the very small. In 2007, the company changed its name to Sigmoid Pharma to reflect its decision to develop a pipeline of proprietary pharmaceutical products.
Sigmoid Pharma is a privately-held, biopharmaceutical development company developing a portfolio Irish Times Innovation Awards - Category Winner of innovative and proprietary orally administered pharmaceutical products in the areas of transplantation, gastro-intestinal disease and neuro-degeneration.
In addition, Sigmoid selectively partners with pharmaceutical companies to enhance the therapeutic profiles of new molecules as well as existing products requiring life cycle management.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about